JPRN-UMIN000032014已完成未知
To identify the presence of type 2 diabetes patients with elevated insulin clearance and clarify there clinical characteristics. - Identification of the presence of type 2 diabetes patients with elevated insulin clearance
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 101
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •ketoacidosis, pregnancy, cancer, thyroid disease, adrenal tumor, renal failure, active infection, inflammatory disease, autoimmune disease, liver cirrhosis, Viral hepatitis, dementia, schizophrenia, and those who did not accept to have hyperinsulinemic-euglycemic clamp examination.
研究者
相似试验
已完成
不适用
EXERFLOW STUDY:The effects of aerobic and resistance exercise training on vascular endothelial function in people with type 2 diabetes mellitusType 2 diabetesVascular function (endothelial function)Metabolic and Endocrine - DiabetesCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12609000799257Baker IDI Heart and Diabetes Institute45
进行中（未招募）
不适用
Development of a non-invasive and accurate diagnostic method for type 2 diabetes using acetone in urine samplesType 2 diabetesNutritional, Metabolic, EndocrineType 2 diabetes mellitusISRCTN12308193Hefei Institutes of Physical Science400
尚未招募
不适用
‘Stepping up’ exercise for type 2 diabetes: a stepped care approach to lifestyle therapytype 2 diabetesMetabolic and Endocrine - DiabetesMetabolic and Endocrine - Other metabolic disordersPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationObesityACTRN12620000027910The University of Queensland80
招募中
不适用
Saiseikai observational study of type 2 diabetics with microangiopathy in relation to macroangiopathyType 2 diabetesJPRN-UMIN000006247SDMac Study Group200
已完成
3 期
Double blind, randomised, comparative, multicentre, parallel-group study design to evaluate the effects of Pioglitazone on cardiovascular risk markers in type 2 diabetes mellitusACTRN12608000534381Takeda Italia Farmaceutici S.p.A.100